LENSAR Reports 6% Revenue Growth to $14.3 Million in Q3 2025 Amid Increased Losses

LENSAR, Inc. reported a total revenue of $14.3 million for the third quarter of 2025, marking a 6% increase from $13.5 million in the same period last year. For the nine months ending September 30, 2025, revenue rose 15% to $42.4 million, up from $36.8 million in 2024. The growth was primarily driven by increased procedure volume and placements of the ALLY Robotic Cataract Laser System. However, the company also reported a net loss of $3.7 million for the quarter, compared to a loss of $1.5 million in the prior year, and a net loss of $32.8 million for the nine-month period, up from $12.7 million in 2024.

The increase in revenue was accompanied by a significant rise in operating expenses, which totaled $13.6 million for the third quarter, nearly doubling from $7.5 million in the same quarter of 2024. This increase was largely attributed to acquisition-related costs associated with the pending merger with Alcon Research, LLC, which amounted to approximately $5.3 million in the third quarter alone. The company’s selling, general, and administrative expenses also surged, reflecting the costs of expanding its sales and marketing efforts to support the ALLY System's growth.

LENSAR's operational metrics showed a total installed base of approximately 425 systems as of September 30, 2025. The company has been actively expanding its commercial organization, which included about 75 sales professionals in the U.S. as of the reporting date. The company’s revenue from the U.S. market represented a significant portion of its total revenue, with U.S. sales accounting for 68% of product and service revenue in the third quarter of 2025.

In terms of liquidity, LENSAR had cash and cash equivalents of $7.6 million as of September 30, 2025, down from $16.3 million at the end of 2024. The company also received a $10 million cash deposit related to the merger, classified as a current liability. Despite the cash decrease, management believes that the available funds, along with anticipated revenue from product sales, will be sufficient to support operations for at least the next twelve months. However, the company acknowledged that ongoing global supply chain disruptions and inflationary pressures could impact future operations and financial performance.

Looking ahead, LENSAR expects to continue incurring losses and cash outflows in the near term, particularly due to acquisition-related costs and the need for further regulatory approvals for the ALLY System. The company is focused on expanding its market presence and product offerings, with plans to increase its sales and marketing efforts in both domestic and international markets. The anticipated merger with Alcon is expected to close in the first quarter of 2026, subject to regulatory approvals and other customary closing conditions.